X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (5907) 5907
rats (4709) 4709
male (3976) 3976
oxidopamine (3159) 3159
neurosciences (2608) 2608
6-hydroxydopamine (1722) 1722
oxidopamine - pharmacology (1675) 1675
rats, sprague-dawley (1582) 1582
hydroxydopamines - pharmacology (1466) 1466
parkinson's disease (1441) 1441
dopamine - metabolism (1333) 1333
index medicus (1331) 1331
rats, inbred strains (1320) 1320
dopamine (1302) 1302
oxidopamine - toxicity (1085) 1085
female (1063) 1063
parkinsons-disease (1045) 1045
corpus striatum - drug effects (956) 956
disease models, animal (952) 952
pharmacology & pharmacy (926) 926
rats, wistar (884) 884
motor activity - drug effects (842) 842
neurons - drug effects (802) 802
corpus striatum - metabolism (784) 784
mice (770) 770
neurons (762) 762
substantia nigra - drug effects (721) 721
dose-response relationship, drug (670) 670
humans (666) 666
dopamine - physiology (659) 659
behavior, animal - drug effects (634) 634
tyrosine 3-monooxygenase - metabolism (602) 602
apomorphine - pharmacology (597) 597
substantia-nigra (589) 589
brain (566) 566
rat (561) 561
striatum (552) 552
time factors (531) 531
neurons - metabolism (528) 528
norepinephrine - metabolism (511) 511
basal ganglia (457) 457
sympathectomy, chemical (452) 452
biochemistry & molecular biology (449) 449
neuroprotective agents - pharmacology (448) 448
oxidative stress (432) 432
substantia nigra - metabolism (430) 430
immunohistochemistry (416) 416
6-ohda (405) 405
neurology (383) 383
brain - drug effects (381) 381
neurons - physiology (381) 381
levodopa - pharmacology (370) 370
stereotyped behavior - drug effects (360) 360
brain - metabolism (351) 351
substantia nigra (336) 336
substantia nigra - physiology (332) 332
norepinephrine - physiology (325) 325
corpus striatum - physiology (324) 324
apoptosis (312) 312
dopamine agonists - pharmacology (312) 312
neuroprotection (309) 309
rotation (309) 309
injections, intraventricular (306) 306
analysis (305) 305
hydroxydopamines (305) 305
cell survival - drug effects (293) 293
in vitro techniques (292) 292
parkinson disease, secondary - chemically induced (291) 291
denervation (286) 286
amphetamine - pharmacology (283) 283
parkinson disease - metabolism (282) 282
parkinsonian disorders - drug therapy (280) 280
parkinsonian disorders - chemically induced (273) 273
substantia nigra - pathology (273) 273
parkinson disease - drug therapy (269) 269
cells, cultured (266) 266
receptors, dopamine - drug effects (266) 266
animals, newborn (262) 262
analysis of variance (255) 255
parkinson’s disease (255) 255
parkinsonian disorders - physiopathology (254) 254
motor activity - physiology (252) 252
nervous system (240) 240
pc12 cells (239) 239
l-dopa (235) 235
adrenergic agents - pharmacology (233) 233
in-vivo (231) 231
parkinsonian disorders - metabolism (230) 230
apomorphine (228) 228
antiparkinson agents - pharmacology (227) 227
parkinson disease - pathology (227) 227
corpus striatum - pathology (226) 226
serotonin - metabolism (225) 225
sympatholytics (224) 224
expression (223) 223
3,4-dihydroxyphenylacetic acid - metabolism (222) 222
mice, inbred c57bl (222) 222
noradrenaline (220) 220
receptors (219) 219
drug interactions (218) 218
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5953) 5953
Russian (59) 59
Chinese (42) 42
Japanese (17) 17
Spanish (9) 9
Ukrainian (8) 8
German (6) 6
French (3) 3
Hungarian (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 09/2012, Volume 122, Issue 5, pp. 941 - 951
J. Neurochem. (2012) 122, 941951. Abstract In vitro and in vivo models of Parkinsons disease (PD) suggest that increased oxidant production leads to... 
hydroethidine | mitochondria | glycolysis | reactive oxygen species | NADPH OXIDASE | OXYGEN SPECIES PRODUCTION | OXIDATIVE STRESS | MECHANISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | DOPAMINERGIC-NEURONS | PARAQUAT | NEUROSCIENCES | BRAIN MITOCHONDRIA | REACTIVE OXYGEN | ANIMAL-MODELS | CELL-CULTURE | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine - pharmacology | Insecticides - pharmacology | Rats | Herbicides - pharmacology | Adrenergic Agents - pharmacology | Dose-Response Relationship, Drug | Neurotoxins - pharmacology | Animals | Oligomycins - pharmacology | Oxidopamine - pharmacology | Time Factors | Dopamine Agents - pharmacology | Oxygen Consumption - drug effects | Adenosine Triphosphate - metabolism | Dopaminergic Neurons - metabolism | Proton Ionophores - pharmacology | Rotenone - pharmacology | Superoxides - metabolism | Dopaminergic Neurons - drug effects | Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone - pharmacology | Paraquat - pharmacology | Cell Line, Transformed | Energy Metabolism - drug effects | Glucose metabolism | Herbicides | Parkinson's disease | Cell death | Analysis | Superoxide | Mitochondrial DNA | Universities and colleges | Cells | Neurochemistry | Mitochondria | Neurotransmitters | Bioenergetics | Parkinsons disease | Apoptosis | Index Medicus | Dopamine | Neurodegenerative diseases | 6-Hydroxydopamine | Acidification | Data processing | Oxygen consumption | Rotenone | Toxicants | MPP super(+) | Oxidants | Glycolysis | Paraquat | Oxidation | Movement disorders
Journal Article
Neuropsychopharmacology, ISSN 0893-133X, 04/2005, Volume 30, Issue 4, pp. 669 - 682
Forebrain serotonergic lesions attenuate the ability of d-amphetamine to decrease impulsivity in a delay-discounting paradigm, potentially through interactions... 
6-OHDA | Impulsivity | Amphetamine | Delay-discounting | 8-OH-DPAT | 5,7-DHT | NUCLEUS-ACCUMBENS DOPAMINE | PSYCHIATRY | DEFICIT HYPERACTIVITY DISORDER | delay-discounting | amphetamine | 5-HT1A RECEPTOR AGONIST | NEUROSCIENCES | REACTION-TIME-TASK | VENTRAL TEGMENTAL AREA | REWARD-RELATED STIMULI | 6-HYDROXYDOPAMINE LESIONS | impulsivity | MEDIAL PREFRONTAL CORTEX | PHARMACOLOGY & PHARMACY | D-AMPHETAMINE | INDUCED LOCOMOTOR-ACTIVITY | Serotonin 5-HT1 Receptor Agonists | Disruptive, Impulse Control, and Conduct Disorders - metabolism | Neural Pathways - drug effects | Nucleus Accumbens - metabolism | Male | Serotonin Receptor Agonists - pharmacology | Dose-Response Relationship, Drug | Oxidopamine - pharmacology | Behavior, Animal - drug effects | Neural Pathways - physiopathology | Dopamine - metabolism | Receptor, Serotonin, 5-HT1A - metabolism | Disruptive, Impulse Control, and Conduct Disorders - drug therapy | Nucleus Accumbens - physiopathology | Amphetamine - pharmacology | Rats | Behavior, Animal - physiology | 5,7-Dihydroxytryptamine - pharmacology | 8-Hydroxy-2-(di-n-propylamino)tetralin - pharmacology | Down-Regulation - drug effects | Serotonin Antagonists - pharmacology | Adrenergic Agents - pharmacology | Piperazines - pharmacology | Disruptive, Impulse Control, and Conduct Disorders - physiopathology | Down-Regulation - physiology | Animals | Norepinephrine - metabolism | Serotonin Agents - pharmacology | Serotonin - metabolism | Neural Pathways - metabolism | Pyridines - pharmacology | Nucleus Accumbens - drug effects
Journal Article
Nature, ISSN 0028-0836, 02/2007, Volume 445, Issue 7128, pp. 643 - 647
The striatum is a major forebrain nucleus that integrates cortical and thalamic afferents and forms the input nucleus of the basal ganglia(1,2). Striatal... 
DOPAMINE D2 RECEPTORS | BASAL GANGLIA | MULTIDISCIPLINARY SCIENCES | GENE-EXPRESSION | NEURONS | HYDROLYSIS | MICE | INTERNEURONS | MODULATION | TERM SYNAPTIC DEPRESSION | PLASTICITY | Cannabinoid Receptor Modulators - metabolism | Receptors, N-Methyl-D-Aspartate - metabolism | Benzoxazines | Long-Term Synaptic Depression - drug effects | Receptors, Dopamine D2 - metabolism | Excitatory Postsynaptic Potentials - drug effects | Psychomotor Performance - physiology | Neostriatum - physiology | Excitatory Postsynaptic Potentials - physiology | Dopamine - deficiency | Neuronal Plasticity - physiology | Oxidopamine - pharmacology | Synapses - metabolism | Neostriatum - drug effects | Piperidines - pharmacology | Reserpine - pharmacology | Benzamides - pharmacology | Parkinson Disease - metabolism | Dopamine - metabolism | Endocannabinoids | Carbamates - pharmacology | Disease Models, Animal | Pyrazoles - pharmacology | Long-Term Synaptic Depression - physiology | Synapses - drug effects | Neostriatum - cytology | Receptors, Dopamine D2 - agonists | Morpholines - pharmacology | Mice, Transgenic | Naphthalenes - pharmacology | Receptor, Cannabinoid, CB1 - metabolism | Animals | Mice | In Vitro Techniques | Dopamine D2 Receptor Antagonists | Brain | Neurosciences | Neurotransmitters | Genetic disorders | Biomedical research | Neurons | Motor ability | Mental depression | Drug therapy
Journal Article
Behavioural Pharmacology, ISSN 0955-8810, 10/2011, Volume 22, Issue 7, pp. 681 - 692
Parkinsonʼs disease psychosis (PDP) is a condition for which a safe, tolerated, and effective therapy is lacking. Treatment with typical or atypical... 
serotonin | substantia nigra | dopamine depletion | rat | Parkinson's disease psychosis | 6-hydroxydopamine lesion | animal model | RISK-FACTORS | D-1 | NEUROSCIENCES | RECEPTOR ANTAGONIST | SEROTONIN 5-HT2A | HALLUCINATIONS | NEURONS | BEHAVIORAL SCIENCES | PHARMACOLOGY & PHARMACY | HEAD-TWITCH BEHAVIOR | MPTP | STRIATUM | Antipsychotic Agents - toxicity | Central Nervous System Stimulants - pharmacology | Amphetamines - pharmacology | Hyperkinesis | Male | Parkinson Disease - drug therapy | Motor Activity | Serotonin Receptor Agonists - pharmacology | Behavior, Animal | Fluorobenzenes - pharmacology | Psychotic Disorders - physiopathology | Piperidines - pharmacology | Antipsychotic Agents - therapeutic use | Urea - toxicity | Urea - analogs & derivatives | Disease Models, Animal | Parkinson Disease - complications | Piperidines - toxicity | Amphetamine - pharmacology | Tyrosine 3-Monooxygenase - analysis | Serotonin 5-HT2 Receptor Antagonists - pharmacology | Fenfluramine - pharmacology | Rats, Sprague-Dawley | Sensory Gating | Dyskinesias - metabolism | Oxidopamine - toxicity | Receptor, Serotonin, 5-HT2A - physiology | Urea - therapeutic use | Animals | Serotonin Agents - pharmacology | Serotonin 5-HT2 Receptor Antagonists - toxicity | Piperidines - therapeutic use | Psychotic Disorders - drug therapy | Antipsychotic Agents - pharmacology | Substantia Nigra - physiology | Urea - pharmacology | Parkinson Disease - etiology
Journal Article
Journal Article
Neuropsychopharmacology, ISSN 0893-133X, 11/2009, Volume 34, Issue 12, pp. 2477 - 2488
Angiogenesis occurs in the brains of Parkinson's disease patients, but the effects of dopamine replacement therapy on this process have not been examined.... 
Angiogenesis | 6-OHDA | Blood-brain barrier | L-DOPA | Dopamine receptors | Dyskinesia | blood-brain barrier | ROTATIONAL BEHAVIOR | PSYCHIATRY | angiogenesis | BASAL GANGLIA | CEREBRAL GLUCOSE-UTILIZATION | dyskinesia | SUBSTANTIA-NIGRA | NEUROSCIENCES | AUTORADIOGRAPHIC LOCALIZATION | dopamine receptors | ADULT-RAT | NITRIC-OXIDE | PHARMACOLOGY & PHARMACY | INDUCED DYSKINESIA | PARS RETICULATA | ENDOTHELIAL GROWTH-FACTOR | Antiparkinson Agents - pharmacology | Aminoacetonitrile - analogs & derivatives | Extracellular Signal-Regulated MAP Kinases - antagonists & inhibitors | Oxidopamine | Receptors, Dopamine D2 - metabolism | Receptors, Dopamine D1 - metabolism | Protease Inhibitors - pharmacology | Dopamine Agents - pharmacology | Parkinsonian Disorders - drug therapy | Receptors, Dopamine D1 - agonists | Female | Neovascularization, Pathologic - physiopathology | Disease Models, Animal | Receptors, Dopamine D1 - antagonists & inhibitors | Levodopa - pharmacology | Parkinsonian Disorders - physiopathology | Receptors, Dopamine D2 - agonists | Rats | Bromocriptine - pharmacology | Parkinsonian Disorders - chemically induced | Benzazepines - pharmacology | Neovascularization, Pathologic - chemically induced | Basal Ganglia - physiology | Rats, Sprague-Dawley | Animals | Neovascularization, Pathologic - drug therapy | Basal Ganglia - blood supply | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine - pharmacology | Aminoacetonitrile - pharmacology | Dopamine D2 Receptor Antagonists | Salicylamides - pharmacology | Basal Ganglia - drug effects | Index Medicus | Basic Medicine | Neurosciences | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper | Neurovetenskaper
Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 10/2005, Volume 95, Issue 1, pp. 68 - 78
Journal Article
Neuropharmacology, ISSN 0028-3908, 12/2008, Volume 55, Issue 8, pp. 1321 - 1328
Convergent evidence suggests that serotonin 5-HT receptor (5-HT R) agonists reduce -DOPA-induced dyskinesia by auto-regulating aberrant release of... 
l-DOPA | Dopamine | Parkinson's disease | D1 receptor | 5-HT1A receptor | Dyskinesia | receptor | 5-HT | DOPA-INDUCED DYSKINESIA | PHARMACOLOGICAL VALIDATION | HUMAN BRAIN POSTMORTEM | 6-HYDROXYDOPAMINE-LESIONED RATS | ABNORMAL INVOLUNTARY MOVEMENTS | NEUROSCIENCES | DEPLETED RAT | LEVODOPA-INDUCED DYSKINESIA | MESSENGER-RNA | L-DOPA | PHARMACOLOGY & PHARMACY | MOTOR COMPLICATIONS | PARKINSONS-DISEASE | Brain Chemistry - drug effects | Chromatography, High Pressure Liquid - methods | Male | Parkinson Disease - drug therapy | Corpus Striatum - metabolism | Receptors, Dopamine D1 - metabolism | Serotonin Receptor Agonists - pharmacology | Adrenergic Agents - toxicity | Desipramine - pharmacology | Time Factors | Functional Laterality - drug effects | Functional Laterality - physiology | Receptor, Serotonin, 5-HT1A - metabolism | Disease Models, Animal | Dopamine Agonists - pharmacology | Parkinson Disease - complications | Parkinson Disease - pathology | Enzyme Inhibitors - pharmacology | Rats | Psychomotor Performance - drug effects | 8-Hydroxy-2-(di-n-propylamino)tetralin - pharmacology | Benzazepines - pharmacology | Serotonin Antagonists - pharmacology | Piperazines - pharmacology | Rats, Sprague-Dawley | Movement Disorders - metabolism | Oxidopamine - toxicity | Animals | Movement Disorders - etiology | Corpus Striatum - drug effects | Pyridines - pharmacology | Biogenic Monoamines - metabolism | Dyskinesia, Drug-Induced - metabolism | Movement Disorders - drug therapy | Index Medicus | Parkinson’s disease
Journal Article
BRITISH JOURNAL OF PHARMACOLOGY, ISSN 0007-1188, 11/2001, Volume 134, Issue 5, pp. 957 - 968
1 To assess the involvement of endothelial alpha (2)-adrenoceptors in the clonidine-induced vasodilatation, the mesenteric artery of Sprague Dawley rats was... 
endothelium mechanisms | clonidine-vasodilatation | nitric oxide | STIMULATION | arterial mesenteric bed | MECHANISM | cyclic GMP | RELAXING FACTOR | ADRENERGIC-RECEPTOR SUBTYPES | RAT TAIL ARTERY | RELEASE | AGONISTS | RESPONSES | HYPERPOLARIZING FACTOR | RESISTANCE VESSELS | L-arginine pathway | PHARMACOLOGY & PHARMACY | Mesenteric Arteries - physiology | Cyclic Nucleotide Phosphodiesterases, Type 5 | Receptors, Adrenergic, alpha-2 - metabolism | Endothelium, Vascular - drug effects | Mesenteric Arteries - drug effects | Adrenergic alpha-Antagonists - pharmacology | Guanylate Cyclase - antagonists & inhibitors | Yohimbine - pharmacology | Dose-Response Relationship, Drug | Quinoxalines - pharmacology | Receptors, Adrenergic, alpha-2 - drug effects | Sildenafil Citrate | Purines | Oxidopamine - pharmacology | Phenylephrine - pharmacology | Time Factors | Oxadiazoles - pharmacology | Sympatholytics - pharmacology | Clonidine - pharmacology | Sulfones | Vascular Resistance | Phosphoric Diester Hydrolases - metabolism | Vasodilator Agents - pharmacology | Acetylcholine - pharmacology | Enzyme Inhibitors - pharmacology | Solubility | Phosphodiesterase Inhibitors - pharmacology | Rats | Guanylate Cyclase - metabolism | Nitric Oxide - physiology | Mesenteric Arteries - metabolism | Piperazines - pharmacology | Rats, Sprague-Dawley | Nitroarginine - pharmacology | Animals | Cyclic GMP - metabolism | Endothelium, Vascular - metabolism | 3',5'-Cyclic-GMP Phosphodiesterases | Adrenergic alpha-Agonists - pharmacology | Vasodilation - drug effects | In Vitro Techniques | Nitric Oxide - metabolism | Saponins - pharmacology
Journal Article
Journal of Neurochemistry, ISSN 0022-3042, 06/2010, Volume 113, Issue 6, pp. 1621 - 1631
J. Neurochem. (2010) 113, 1621–1631. Increasing evidence suggests that glucagon‐like peptide‐1 (GLP‐1), an incretin hormone of current interest in type 2... 
exendin‐4 | glucagon‐like peptide‐1 | neuroprotection | oxidative stress | Parkinson’s disease | 6‐hydroxydopamine | Neuroprotection | Oxidative stress | 6-hydroxydopamine | Glucagon-like peptide-1 | Parkinson's disease | Exendin-4 | ALZHEIMERS-DISEASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | glucagon-like peptide-1 | ENDOPLASMIC-RETICULUM STRESS | HIPPOCAMPAL-NEURONS | NEUROSCIENCES | BETA | RODENT MODELS | ANIMAL-MODEL | BLOOD-BRAIN | exendin-4 | PARKINSONS-DISEASE | Nitriles - pharmacology | Apoptosis - drug effects | Humans | Caspase 3 - metabolism | Neuroblastoma | Adrenergic Agents - toxicity | Dose-Response Relationship, Drug | Proto-Oncogene Proteins c-bcl-2 - metabolism | Neuroprotective Agents - pharmacology | Transfection - methods | Time Factors | Bromodeoxyuridine - metabolism | Cyclic AMP - metabolism | Cell Survival - physiology | Hydrogen Peroxide - toxicity | Receptors, Glucagon - genetics | Cell Survival - drug effects | Butadienes - pharmacology | Colforsin - pharmacology | Enzyme Inhibitors - pharmacology | Glucagon-Like Peptide 1 - pharmacology | Oxidants - toxicity | bcl-2-Associated X Protein - metabolism | Receptors, Glucagon - metabolism | Hypoglycemic Agents - pharmacology | Peptides - pharmacology | Oxidopamine - toxicity | Activating Transcription Factor 4 - metabolism | Glucagon-Like Peptide-1 Receptor | Signal Transduction - drug effects | Cell Line, Tumor | Signal Transduction - physiology | Cell Proliferation - drug effects | Venoms - pharmacology | Type 2 diabetes | Neurosciences | Nervous system diseases | Hydrogen peroxide | Peptides | Analysis | Protein kinases | Neurology | Cell culture | Biochemistry | Hormones | GLP-1
Journal Article
Neuropharmacology, ISSN 0028-3908, 03/2013, Volume 66, pp. 158 - 169
Group III metabotropic glutamate (mGlu) receptors are localized in presynaptic terminals within basal ganglia (BG) circuitry that become hyperactive due to... 
Striatum | Basal ganglia | Akinesia | Rat | Lu AF21934 | l-DOPA-induced dyskinesia | Electrophysiology | HIGH-FREQUENCY STIMULATION | NEUROLOGICAL DISEASES | NEUROSCIENCES | RAT MODEL | STRIATAL SYNAPTIC PLASTICITY | MEDIATED MODULATION | SUBTHALAMIC NUCLEUS | UNILATERAL 6-HYDROXYDOPAMINE LESIONS | PHARMACOLOGY & PHARMACY | DEEP BRAIN-STIMULATION | L-DOPA-induced dyskinesia | MOLECULAR-MECHANISMS | Anilides - therapeutic use | Catalepsy - drug therapy | Synaptic Transmission - physiology | Excitatory Amino Acid Agonists - therapeutic use | Receptors, Metabotropic Glutamate - physiology | Male | Aminobutyrates - pharmacology | Anilides - pharmacokinetics | Parkinson Disease - drug therapy | Oxidopamine | Aminobutyrates - therapeutic use | Excitatory Postsynaptic Potentials - drug effects | Dose-Response Relationship, Drug | Excitatory Postsynaptic Potentials - physiology | Haloperidol - antagonists & inhibitors | Allosteric Regulation - physiology | Dyskinesia, Drug-Induced - drug therapy | Catalepsy - chemically induced | Synaptic Transmission - drug effects | Haloperidol - pharmacology | Disease Models, Animal | Allosteric Regulation - drug effects | Aminobutyrates - agonists | Levodopa - pharmacology | Cyclohexanecarboxylic Acids - therapeutic use | Phosphinic Acids - agonists | Levodopa - therapeutic use | Phosphinic Acids - therapeutic use | Rats | Excitatory Amino Acid Agonists - pharmacology | Rats, Sprague-Dawley | Drug Synergism | Animals | Cyclohexanecarboxylic Acids - pharmacology | Levodopa - adverse effects | Phosphinic Acids - pharmacology | Anilides - pharmacology | Excitatory Amino Acid Agonists - pharmacokinetics | Cyclohexanecarboxylic Acids - pharmacokinetics | Receptors, Metabotropic Glutamate - agonists | Receptors, Metabotropic Glutamate - antagonists & inhibitors | Physiological aspects | Phenols | Amino acids | Parkinson's disease | Glutamate | Drug therapy | 6-Hydroxydopamine | Phosphinic Acids | Excitatory Amino Acid Agonists | Allosteric Regulation | Catalepsy | Haloperidol | Aminobutyrates | Cellular Biology | Synaptic Transmission | Receptors, Metabotropic Glutamate | Parkinson Disease | Anilides | Life Sciences | Excitatory Postsynaptic Potentials | Cyclohexanecarboxylic Acids | Dyskinesia, Drug-Induced | Levodopa
Journal Article